ML-007

ML-007 is a selective muscarinic acetylcholine M₁ and M₄ receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias.^[1][2][3][4] It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC).^[4][3] The drug is taken by mouth.^[1]

ML-007

Clinical data
Other names	ML007; ML-007/PAC; ML007/PAC
Routes of administration	Oral[1]
Drug class	Muscarinic acetylcholine M1 and M4 receptor agonist[1]

As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias.^[1][2][3] It is under development by MapLight Therapeutics.^[1][2] The drug is a small molecule, but its chemical structure does not seem to have been disclosed.^[4][1][2]

See also

• Emraclidine
• NBI-1117568
• NS-136
• Xanomeline/trospium